Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by Relaxrelaxon Feb 21, 2018 10:16am
288 Views
Post# 27593480

Well this announcement has me confused?

Well this announcement has me confused?So Alstrm Syndrome, a very rare disease in the UK and IPF are the new priorities?  Not a mention of 4050 and type 2 diabetes anywhere in the statement.  That was the reason I got in the stock was the huge potential they were hyping 4050 and type 2 diabetes.  Now that’s where I thought the huge market would be.  Are they not telling us that this potential cure is done?  If anyone has some info on where PLI stands on their tests with diabetes can you please share.  I’ve read this latest news release several times and I’m more confused than ever.
Bullboard Posts